Evidence map›Paper›PMID 38985396›Full record

ArticleJournal of fluorescence2025

Synthesis of two Fluorescent Complexes and Their use as Multifunctional Nanomedicine Carriers for Rhabdomyosarcoma Treatment.

Ping Yang, Peng Xie, Feng Lin, Tian Wang, Lian Zhang, Fei Yan

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ping YangDepartment of Oncology, The Eighth People's Hospital of Shanghai, Shanghai, 200233, China.
Peng XieDepartment of Orthopedics, The Third Affliated Hospital The Affliated Luohu Hospital of Shenzhen University, Shenzhen, 518000, China.
Feng LinDepartment of Oncology, The Eighth People's Hospital of Shanghai, Shanghai, 200233, China.
Tian WangDepartment of Oncology, The Eighth People's Hospital of Shanghai, Shanghai, 200233, China.
Lian ZhangDepartment of Oncology, The Eighth People's Hospital of Shanghai, Shanghai, 200233, China.
Fei YanDepartment of Oncology, The Eighth People's Hospital of Shanghai, Shanghai, 200233, China. yanfei1136@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study focuses on the design and synthesis of two novel coordination polymers (CPs), named 1 and 2, with excellent fluorescent properties. Their structures were characterized by X-ray single-crystal diffraction, revealing that both materials exhibit promising fluorescence performance, indicating their potential as fluorescent detection tools. Additionally, 1 was chosen to be combined with chitosan (CS), resulting in the successful fabrication of a biodegradable and non-toxic efficient drug carrier, termed CS-1@Cisplatin. This carrier possesses a large surface area and good solubility, enabling sustained drug release to target cells. Given that CXC motif chemokine receptor type 4 (CXCR4) is a key marker gene highly expressed in Rhabdomyosarcoma (RMS) cells and tissues, RMS was chosen as the biological model for testing. The results demonstrated that CS-1@Cisplatin effectively inhibited the invasiveness of RMS cells by significantly suppressing CXCR4 expression. Therefore, the system shows great potential for applications in RMS treatment, biometrics, and drug delivery, particularly in its unique advantage of targeting RMS by inhibiting the key marker gene CXCR4.

Indexed as

Antineoplastic AgentsCisplatinCoordination ComplexesDrug CarriersFluorescent DyesNanomedicineRhabdomyosarcomaCell Line, TumorCell ProliferationChitosanHumansReceptors, CXCR4Antineoplastic AgentsChitosanCisplatinCoordination ComplexesCXCR4 protein, humanDrug CarriersFluorescent DyesReceptors, CXCR4ComplexCXCR4FluorescentNanomedicineRMS

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.